載入...
Activity-based protein profiling shows heterogeneous signaling adaptations to BRAF inhibition
Patients with BRAF V600E mutant melanoma are typically treated with targeted BRAF kinase inhibitors, such as vemurafenib and dabrafenib. Although these drugs are initially effective, they are not curative. Most of the focus to date has been upon genetic mechanisms of acquired resistance; therefore,...
Na minha lista:
| 發表在: | J Proteome Res |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5642956/ https://ncbi.nlm.nih.gov/pubmed/27934295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jproteome.6b00613 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|